NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Note 1 — Organization and Business Operations
Organization and General
Mission Advancement Corp.
was incorporated in Delaware on December 22, 2020. The Company was formed for the purpose of entering into a business combination. The
Company is not limited to a particular industry or geographic region for purposes of consummating a business combination. The Company
is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.
As of September 30, 2022,
the Company had not yet engaged in any operations or generated any revenues to date. All activity through September 30, 2022, relates
to the Company’s formation and the initial public offering (described below) and identifying a target company for our initial business
combination. The Company will not generate any operating revenues until after the completion of its initial business combination, at the
earliest. The Company generates non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived
from the IPO.
Financing
The registration statement
for the Company’s IPO was declared effective on March 2, 2021. On March 5, 2021, the Company consummated the IPO of 34,500,000 units,
at $10.00 per unit, generating gross proceeds of $345,000,000, which is discussed in Note 3.
Simultaneously with the closing
of the IPO, the Company consummated the sale of 5,933,333 private placement warrants, at a price of $1.50 per private
placement warrant, which is discussed in Note 4.
Transaction costs amounted
to $19,634,742 consisting of $6,900,000 of underwriting fee, $12,075,000 of deferred underwriting fee and $659,742 of
other offering costs. Of the total transaction costs $864,511 was expensed as non-operating expenses in the statements of operations
with the rest of the offering cost charged to temporary equity. The transaction costs were allocated based on the relative fair value
basis, compared to the total offering proceeds, between the fair value of the public warrant liabilities and the Class A common stock.
Trust Account
Following the closing of the IPO on March 5, 2021, an amount of $345,000,000 from
the net proceeds of the sale of the units in the IPO and the sale of the private placement warrants was placed in the trust account, which
is invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a
maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions
of Rule 2a-7 of the Investment Company Act, as determined by the Company. Except with respect to interest earned on the funds held in
the trust account that may be released to the Company to pay its tax obligations, the proceeds from the IPO and the sale of the private
placement units will not be released from the trust account until the earliest of (a) the completion of the Company’s initial business
combination, (b) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s
charter, and (c) the redemption of the Company’s public shares if the Company is unable to complete the initial business combination
within 24 months from the closing of the IPO, subject to applicable law. The proceeds deposited in the trust account could become subject
to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders.
Initial Business Combination
The Company’s management
has broad discretion with respect to the specific application of the net proceeds of the IPO, although substantially all of the net proceeds
are intended to be generally applied toward consummating a business combination.
The Company’s business
combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance
in the trust account (net of taxes payable) at the time of the signing an agreement to enter into a business combination. However, the
Company will only complete a business combination if the post-business combination company owns or acquires 50% or more of the outstanding
voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register
as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect
a business combination.
The Company will provide
its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial business
combination either (i) in connection with a stockholder meeting called to approve the initial business combination or (ii) by means of
a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial business combination or conduct
a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro
rata portion of the amount then on deposit in the trust account (initially $10.00 per share, plus any pro rata interest earned on
the funds held in the trust account and not previously released to the Company to pay its tax obligations).
The shares of common stock
subject to redemption is recorded at a redemption value and classified as temporary equity upon the completion of the IPO, in accordance
with ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”). In such case, the Company will proceed
with a business combination if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon consummation
of a business combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted
in favor of the business combination.
The Company has until March
5, 2023, 24 months from the closing of the IPO, to consummate a business combination. However, if the Company is unable to complete a
business combination within the Combination Period, the Company will redeem 100% of the outstanding public shares for a pro rata
portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest
earned on the funds held in the trust account and not previously released to the Company, divided by the number of then outstanding public
shares, subject to applicable law and as further described in the registration statement, and then seek to dissolve and liquidate.
The Company’s sponsor, Mission Advancement Sponsor LLC, officers
and directors have agreed to (i) waive their redemption rights with respect to their (x) founder shares, (y) shares underlying their private
placement warrants (“private placement shares”) and (z) public shares in connection with the completion of the initial business
combination, (ii) waive their redemption rights with respect to their founder shares and public shares in connection with a stockholder
vote to approve an amendment to the Company’s charter, and (iii) waive their rights to liquidating distributions from the trust
account with respect to their founder shares and private placement shares if the Company fails to complete the initial business combination
within the Combination Period.
The Company’s sponsor
has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold
to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or
similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.00 per
public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account,
if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability
will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies
held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity
of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. However, the Company has not
asked its sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its sponsor has
sufficient funds to satisfy its indemnity obligations and believe that the Company’s sponsor’s only assets are securities
of the Company. Therefore, the Company cannot assure that its sponsor would be able to satisfy those obligations.
Liquidity and Capital Resources
As of September 30, 2022,
the Company had cash outside the trust account of $132,012 available for working capital needs, respectively. As of September 30, 2022,
$320,500 in the trust account was withdrawn to pay taxes. As of September 30, 2022, all remaining cash held in the trust account is generally
unavailable for the Company’s use, prior to an initial business combination, and is restricted for use either in a business combination
or to redeem common stock.
Through September 30, 2022,
the Company’s liquidity needs were satisfied through receipt of $25,000 from the sale of the founder shares and the remaining
net proceeds from the IPO and the sale of private placement warrants.
Going Concern
The Company anticipates that
the $132,012 held outside of the trust account as of September 30, 2022, might not be sufficient to allow the Company to operate until
March 5, 2023, the end of the Combination Period, assuming that a business combination is not consummated during that time. Until consummation
of its business combination, the Company will be using the funds not held in the trust account, and any additional Working Capital Loans
from the initial stockholders, the Company’s officers and directors, or their respective affiliates (which is described in Note
5), for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses,
traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material
agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the
business combination.
The Company can raise additional
capital through Working Capital Loans from the initial stockholders, the Company’s officers, directors, or their respective affiliates
(which is described in Note 5), or through loans from third parties. None of the sponsor, officers or directors are under any obligation
to advance funds to, or to invest in, the Company. If the Company is unable to raise additional capital, it may be required to take additional
measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit
of its business plan, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to
it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue
as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements.
The Company has until March
5, 2023, 24 months from the closing of the IPO, to consummate a business combination. It is uncertain that we will be able consummate
a business combination within the Combination Period. If a business combination is not consummated within the Combination Period, there
will be a mandatory liquidation and subsequent dissolution. In connection with the Company’s assessment of going concern considerations
in accordance with the authoritative guidance ASU Topic 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to
Continue as a Going Concern”, management has determined that mandatory liquidation, and subsequent dissolution, should the Company
be unable to complete a business combination, raises substantial doubt about the Company’s ability to continue as a going concern.
No adjustments have been made to the carrying amounts of assets and liabilities should the Company be required to liquidate after March
5, 2023.
Risks and Uncertainties
Management is currently evaluating
the impact of the COVID-19 pandemic and the Russia-Ukraine war and has concluded that while it is reasonably possible that the virus and
war could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company,
the specific impact is not readily determinable as of the date of these unaudited condensed financial statements. The accompanying unaudited
condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Note 2 — Significant Accounting Policies
Basis of Presentation
The accompanying unaudited
condensed financial statements have been prepared in accordance with US GAAP for interim financial information and in accordance with
the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included
in unaudited condensed financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant to the rules
and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary
for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying
unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair
presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited
condensed financial statements should be read in conjunction with the Company’s Form 10-K for the year ended December 31, 2021 as
filed with the SEC on April 1, 2022, which contains the audited financial statements and notes thereto. The interim results for the three
and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31,
2022 or for any future interim periods.
Emerging Growth Company Status
The Company is an “emerging
growth company,” as defined in Section 2(a) of the Securities Act, as modified by JOBS Act, and it may take advantage of certain
exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including,
but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced
disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved.
Further, Section 102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.
Use of Estimates
The preparation of unaudited
condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Inflation Reduction Act of 2022
On August 16, 2022, the IR
Act was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases
(including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded
foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased.
The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However,
for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock
issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the
excise tax. The Treasury Department has been given authority to provide regulations and other guidance to carry out, and prevent the abuse
or avoidance of the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022.
Any redemption or other repurchase that occurs after December 31, 2022,
in connection with a Redemption Event may be subject to the excise tax. Whether and to what extent we would be subject to the excise tax
in connection with a Redemption Event would depend on a number of factors, including (i) the fair market value of the redemptions and
repurchases in connection with the Redemption Event, (ii) the structure of the business combination, (iii) the nature and amount of any
“PIPE” or other equity issuances in connection with the business combination (or otherwise issued not in connection with the
Redemption Event but issued within the same taxable year of the business combination) and (iv) the content of regulations and other guidance
from the Treasury Department. In addition, because the excise tax would be payable by us, and not by the redeeming holder, the mechanics
of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand
to complete a business combination and in our ability to complete a business combination.
Marketable Securities Held in Trust Account
At September 30, 2022 and
December 31, 2021, the trust account had $346,698,074 and $345,018,988 held in marketable securities, respectively. During the nine
months ended September 30, 2022, and 2021, the Company withdrew $320,500 and $0 from the trust account to pay its tax obligations,
respectively. Marketable securities held in trust account are classified as “Held-for-Trading Securities” and are reported
at fair value with unrealized gains or losses included in earnings of the current period.
Common Stock Subject to Possible Redemption
The Company accounts for
its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Class A common stock subject to mandatory
redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including
common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence
of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock
is classified as stockholders’ deficit. The Company’s common stock feature certain redemption rights that are considered to
be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2022
and December 31, 2021, 34,500,000 shares of Class A common stock subject to possible redemption are presented at redemption
value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheets.
Net Income per Common Stock
The Company complies with
accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” The Company’s statements of operations include
a presentation of income per share for Class A common stock subject to possible redemption in a manner similar to the two-class method
of income per share. The contractual formula utilized to calculate the redemption amount approximates fair value. The Class A common stock
feature to redeem at fair value means that there is effectively only one class of stock. Changes in fair value are not considered a dividend
of the purposes of the numerator in the earnings per share calculation. Net income per share is computed by dividing the pro rata net
income between the Class A shares and the Class B shares by the weighted average number of shares outstanding for each of the periods.
The calculation of diluted income per share does not consider the effect of the warrants and rights issued in connection with the IPO
since the exercise of the warrants and rights are contingent upon the occurrence of future events and the inclusion of such warrants would
be anti-dilutive.
The Company did not have
any dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and then share in the
earnings of the Company. As a result, diluted income per share is the same as basic income per share for the period presented.
Below is a reconciliation
of the net income per common stock:
| |
For the Three Months Ended
September 30, | |
| |
2022 | | |
2021 | |
Redeemable Class A common stock | |
| | |
| |
Numerator: | |
| | |
| |
Net income allocable to Class A common stock subject to possible redemption | |
$ | 1,509,415 | | |
$ | 3,231,012 | |
Denominator: | |
| | | |
| | |
Weighted average redeemable Class A common stock, Basic and Diluted | |
| 34,500,000 | | |
| 34,500,000 | |
Basic and diluted net income per share, redeemable Class A common stock | |
$ | 0.04 | | |
$ | 0.09 | |
| |
| | | |
| | |
Non-redeemable common stock | |
| | | |
| | |
Numerator: | |
| | | |
| | |
Net income allocable to non-redeemable Class B common stock | |
$ | 377,354 | | |
$ | 807,753 | |
Denominator: | |
| | | |
| | |
Weighted average non-redeemable Class B common stock | |
| 8,625,000 | | |
| 8,625,000 | |
Basic and diluted net income per share, non-redeemable Class B common stock | |
$ | 0.04 | | |
$ | 0.09 | |
| |
For the Nine Months Ended
September 30, | |
| |
2022 | | |
2021 | |
Redeemable Class A common stock | |
| | |
| |
Numerator: | |
| | |
| |
Net income allocable to Class A common stock subject to possible redemption | |
$ | 7,442,405 | | |
$ | 8,434,751 | |
Denominator: | |
| | | |
| | |
Weighted average redeemable Class A common stock, Basic and Diluted | |
| 34,500,000 | | |
| 26,538,462 | |
Basic and diluted net income per share, redeemable Class A common stock | |
$ | 0.22 | | |
$ | 0.32 | |
| |
| | | |
| | |
Non-redeemable common stock | |
| | | |
| | |
Numerator: | |
| | | |
| | |
Net income allocable to non-redeemable Class B common stock | |
$ | 1,860,601 | | |
$ | 2,571,464 | |
Denominator: | |
| | | |
| | |
Weighted average non-redeemable Class B common stock | |
| 8,625,000 | | |
| 8,090,659 | |
Basic and diluted net income per share, non-redeemable Class B common stock | |
$ | 0.22 | | |
$ | 0.32 | |
Offering Costs
The Company complies with
the requirements of the ASC Topic 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A, “Expenses of Offering”. Offering
costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the initial
public offering and that were charged to stockholders’ deficit upon the completion of the IPO. Accordingly, on March 5, 2021, offering
costs totaling $19,634,742 have been charged to temporary equity (consisting of $6,900,000 of underwriting fee, $12,075,000 of
deferred underwriting fee and $659,742 of other offering costs). Of the total transaction costs $864,511 was reclassed to expense
as a non-operating expense in the statements of operations with the rest of the offering cost charged to temporary equity. The transaction
costs were allocated based on the relative fair value basis, compared to the total offering proceeds, between the fair value of the public
warrant liabilities and the Class A common stock.
Fair Value of Financial Instruments
The fair value of the Company’s
assets and liabilities, which qualify as financial instruments under the ASC Topic 820, “Fair Value Measurements and Disclosures,”
approximates the carrying amounts represented in the balance sheet.
Fair Value Measurements
“Fair value”
is defined as “the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction
between market participants at the measurement date”. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the
inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
|
● |
Level 1, defined as “observable inputs such as quoted prices (unadjusted) for identical instruments in active markets”; |
|
● |
Level 2, defined as “inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active”; and |
|
● |
Level 3, defined as “unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable”. |
Derivative Warrant Liabilities
The Company does not use
derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial
instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify
as embedded derivatives, pursuant to ASC 480 and ASC Topic 815-15, “Derivatives and Hedging”. The classification of derivative
instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting
period.
The Company accounts for
its 17,433,333 common stock warrants issued in connection with its IPO 11,500,000 and private placement 5,933,333 as derivative
warrant liabilities in accordance with ASC Topic 815-40, “Derivatives and Hedging”. Accordingly, the Company recognizes the
warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are
subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s
statements of operations. At the IPO, the Company utilized a Monte Carlo simulation model to determine the initial value of the public
warrants and private placement warrants. At September 30, 2022 and December 31, 2021, the Company used the quoted stock price in the active
market to value the public warrants and a Monte Carlo simulation model to value the private placement warrants with changes in fair value
charged to the statements of operations.
Income Taxes
The Company accounts for
income taxes under ASC Topic 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax
assets and liabilities for both the expected impact of differences between the unaudited condensed financial statements and tax basis
of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally
requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not
be realized. As of September 30, 2022 and December 31, 2021, the Company’s deferred tax asset had a full valuation allowance recorded
against it.
ASC 740 also clarifies the
accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold
and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.
ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in annual period, disclosure and transition.
ASC
740-270-25-2 requires that an annual effective tax rate be determined and such annual effective rate applied to year to date income in
interim periods under ASC 740-270-30-5. Our effective tax rate was 14.11% and
0.00% for the three months ended September 30, 2022, and 2021, respectively, and 3.64% and 0.00% for the nine months ended September 30,
2022, and 2021, respectively. The effective tax rate differs from the statutory tax rate of 21% for the three and nine months ended September
30, 2022, and 2021, due to changes in fair value in warrant liability and the valuation allowance on the deferred tax assets.
The Company recognizes accrued
interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts
accrued for interest and penalties as of September 30, 2022, and December 31, 2021. The Company is currently not aware of any issues under
review that could result in significant payments, accruals or material deviation from its position.
The Company may be subject
to potential examination by federal and state taxing authorities in the areas of income taxes. These potential examinations may include
questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state
tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over
the next twelve months.
Recent Accounting Standards
The Company’s management
does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect
on the accompanying financial statements.
Note 3 — Initial Public Offering
Pursuant to the IPO, the
Company sold 34,500,000 units, (at a price of $10.00 per unit). Each unit consists of one share of Class A common stock,
par value $0.0001 per share and one-third of one public warrant. Each whole public warrant entitles the holder to purchase one share
of Class A common stock at a price of $11.50 per share.
Note 4 — Private Placement Warrants
Simultaneously with the closing
of the IPO, the sponsor purchased an aggregate of 5,933,333 private placement warrants at a price of $1.50 per warrant
($8,900,000 in the aggregate), each private placement warrant is exercisable to purchase one share of Class A common stock at a price
of $11.50 per share. A portion of the purchase price of the private placement warrants was added to the proceeds from the IPO being
held in the trust account.
The private placement warrants
will not be redeemable by the Company so long as they are held by the initial purchasers or their permitted transferees. The initial purchasers,
or their permitted transferees, have the option to exercise the private placement warrants on a cashless basis. If the private placement
warrants are held by holders other than initial purchasers or their permitted transferees, the private placement warrants will be redeemable
by the Company and exercisable by the holders on the same basis as the warrants included in the units sold in the initial public offering.
Otherwise, the private placement warrants have terms and provisions that are identical to those of the warrants being sold as part of
the units in the initial public offering.
Note 5 — Related Party Transactions
Founder
Shares
On December 22, 2020, the
sponsor paid $25,000, or approximately $0.003 per share, to cover certain offering costs in consideration for the founder shares,
7,187,500 shares of Class B common stock, par value $0.0001. On March 2, 2021, the Company effected a stock dividend of approximately 0.2 shares
for each share of Class B common stock outstanding, resulting in the sponsor holding on aggregate of 8,625,000 founder shares.
The Company’s initial
stockholders have agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of (A) one year after
the completion of the Company’s initial business combination and (B) the date on which the Company completes a liquidation,
merger, capital stock exchange or other similar transaction after the Company’s initial business combination that results in all
of the Company’s stockholders having the right to exchange their Class A common stock for cash, securities or other property;
except to certain permitted transferees and under certain circumstances. Any permitted transferees will be subject to the same restrictions
and other agreements of the Company’s initial stockholders with respect to any founder shares. The Company refers to such transfer
restrictions as the “lock-up”. Notwithstanding the foregoing, the founder shares will be released from the lockup if
the closing price of the Company’s Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock
capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing
at least 150 days after the company’s initial business combination.
On February 11, 2021, the
Sponsor transferred 265,000 founder shares to fifteen (15) of the Company’s directors and advisors in recognition of and compensation
for their future services to the Company. The assignment of the founders shares to the Company’s directors and advisors is within
the scope of ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation
associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 265,000 founder
shares granted to the Company’s directors and advisors was $1,648,300 or $6.22 per share. The founder shares were effectively
assigned to the directors and advisors subject to a performance condition (i.e., the consummation of a business combination). Compensation
expense related to the founder shares is recognized only when the performance condition is probable of achievement under the applicable
accounting literature. Stock-based compensation would be recognized at the date a business combination is considered probable in an amount
equal to the number of founder shares times the grant date fair value per share (unless subsequently modified) less the amount initially
received for the purchase of the founder shares. As of September 30, 2022 and December 31, 2021, the Company has not yet entered into
any definitive agreements in connection with any business combination. Any such agreements may be subject to certain conditions to closing,
such as, for example, approval by the Company’s stockholders. As a result, the Company determined that the consummation of a business
combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized.
On September 14, 2022, the
terms of the share assignment of the Founders Shares to directors were modified further to include additional restrictions. This modification
resulted in the incremental value of $213,000 of the total value of the assignment, or $2.13 per modified share. Modification of the terms
of the share assignment to the directors did not impact vesting period of the assigned shares.
Promissory Note — Related Party
On
December 22, 2020, the sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the IPO .
These loans were non-interest bearing, unsecured and were due at the earlier of September 30, 2021 or
the closing of the IPO. As of September 30, 2022 and December 31, 2021, the Company had no outstanding borrowings under the promissory
note.
Working Capital Loans
In addition, in order to
finance transaction costs in connection with a business combination, the initial stockholders or an affiliate of the initial stockholders
or certain of the Company’s directors and officers may, but are not obligated to, loan the Company Working Capital Loans. If the
Company completes a business combination, the Company would repay the Working Capital Loans out of the proceeds of the trust account released
to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the trust account. In the event that
a business combination does not close, the Company may use a portion of proceeds held outside the trust account to repay the Working Capital
Loans, but no proceeds held in the trust account would be used to repay the Working Capital Loans. Except for the foregoing, the terms
of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working
Capital Loans would either be repaid upon consummation of a business combination, without interest, or, at the lender’s discretion,
up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-business combination entity at a price
of $1.50 per warrant. The warrants would be identical to the private placement warrants.
On December 1, 2021, the
Company issued the Note, a promissory note in the principal amount of up to $1,500,000 to the sponsor. The Note was issued in connection
with advances the sponsor has made, and may make in the future, to the Company for working capital expenses. The Note bears no interest
and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and
(ii) the date of the liquidation of the Company. At the election of the sponsor, all or a portion of the unpaid principal amount of the
Note may be converted into warrants of the Company, each warrant exercisable for one share of Class A common stock of the Company
upon the consummation of an initial business combination (the “Conversion Warrants”), equal to: (x) the portion of the principal
amount of the Note being converted, divided by (y) $1.50, rounded up to the nearest whole number of warrants. The Conversion Warrants
are identical to the warrants issued by the Company to the Sponsor in a private placement in connection with the Company’s IPO.
The Conversion Warrants and their underlying securities are entitled to the registration rights set forth in the Note. As of September
30, 2022 and December 31, 2021, the outstanding balance of the Note was $950,000 and $550,000, respectively.
The conversion feature included
in the Note is considered an embedded derivate and is remeasured at the end of each reporting period. The value is de minimis.
Administrative Support Agreement
Commencing
on the date of the IPO, the Company has agreed to pay the sponsor a total of $10,000 per month for office space and administrative
support services. Upon completion of the initial business combination or the Company’s liquidation, the Company will cease paying
these monthly fees. The Company incurred $30,000 for the three months ended September 30, 2022 and 2021. The Company incurred $90,000 and
$69,677 for the nine months ended September 30, 2022
and 2021, respectively.
Note 6 — Commitments & Contingencies
Registration Rights
The holders of the founder
shares, private placement warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A common
stock issuable upon the exercise of the private placement warrants and warrants issued upon conversion of the Working Capital Loans) will
be entitled to registration rights pursuant to a registration rights agreement that was signed prior to or on the effective date of the
IPO. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register
such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements
filed subsequent to consummation of a business combination. However, the registration rights agreement provides that the Company will
not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period.
The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriters Agreement
On March 5, 2021, the Company
paid a fixed underwriting discount of $0.20 per unit, or $6,900,000 in the aggregate. Additionally, a deferred underwriting discount of
$0.35 per unit, or $12,075,000 in the aggregate, will be payable to the underwriters from the amounts held in the trust account solely
in the event that the Company completes an initial business combination, subject to the terms of the underwriting agreement.
Note 7 — Stockholders’ Equity (Deficit)
Preferred Stock
The Company is authorized
to issue a total of 1,000,000 shares of preferred stock at par value of $0.0001 each. As of September 30, 2022 and December
31, 2021, there were no shares of preferred stock issued or outstanding.
Class A Common Stock
The Company is authorized
to issue a total of 300,000,000 shares of Class A common stock at par value of $0.0001 each. As of September 30, 2022 and
December 31, 2021, there were no shares issued and outstanding (excluding 34,500,000 shares subject to possible redemption).
Class B Common Stock
The Company is authorized
to issue a total of 20,000,000 shares of Class B common stock at par value of $0.0001 each. As of September 30, 2022 and
December 31, 2021, there were 8,625,000 shares of Class B common stock issued or outstanding.
Holders of Class A common stock and holders of Class B common
stock will vote together as a single class on all matters submitted to a vote of the Company’s stockholders except as required by
law. Unless specified in the Company’s charter, or as required by applicable provisions of the DGCL or applicable stock exchange
rules, the affirmative vote of a majority of the Company’s shares of common stock that are voted is required to approve any such
matter voted on by its stockholders.
The Class B common stock
will automatically convert into Class A common stock upon the consummation of the initial business combination on a one-for-one basis,
subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and subject to further adjustment.
In the case that additional shares of Class A common stock or equity-linked securities are issued or deemed issued in connection
with the initial business combination, the number of Class A common stock issuable upon conversion of all founder shares will equal,
in the aggregate, on an as-converted basis, 20% of the total number of shares of Class A common stock outstanding after such
conversion, including the total number of shares of Class A common stock issued, or deemed issued or issuable upon conversion or
exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation
of the initial business combination, excluding any shares of Class A common stock or equity-linked securities or rights exercisable
for or convertible into shares of Class A common stock issued, or to be issued, to any seller in the initial business combination
and any private placement warrants issued to the sponsor, officers or directors upon conversion of Working Capital Loans; provided that
such conversion of founder shares will never occur on a less than one-for-one basis.
Note 8 — Warrants
Each whole warrant entitles
the holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment as discussed
below, at any time commencing on the later of 12 months from the closing of the IPO and 30 days after the completion of the initial
business combination, provided in each case that the Company has an effective registration statement under the Securities Act covering
the shares of Class A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available
(or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement)
and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence
of the holder. The warrants will expire five years after the completion of the Company’s initial business combination,
at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
The Company has agreed that
as soon as practicable, but in no event later than fifteen (15) business days after the closing of the initial business combination, it
will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class A
common stocks issuable upon exercise of the warrants. The Company will use its best efforts to cause the same to become effective and
to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration or redemption
of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the shares of Class A
common stock issuable upon exercise of the warrants is not effective by the sixtieth (60th) business day after the closing
of the initial business combination, warrant holders may, until such time as there is an effective registration statement and during any
period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis”
in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Company’s
Class A common stock are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy
the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option,
require holders of public warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9)
of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement,
and in the event the Company does not so elect, it will use its best efforts to register or qualify the shares under applicable blue sky
laws to the extent an exemption is not available.
Once the warrants become
exercisable, the Company may call the warrants for redemption for cash:
|
● |
in whole and not in part; |
|
|
|
|
● |
at a price of $0.01 per warrant; |
|
|
|
|
● |
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and |
|
|
|
|
● |
if, and only if, the closing price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three business days before the Company sends to the notice of redemption to the warrant holders. |
In addition, if (x) the
Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with
the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of Class A
common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors
and, in the case of any such issuance to the initial stockholders or their affiliates, without taking into account any founder shares
held by the initial stockholders or such affiliates, as applicable, prior to such issuance), (the “Newly Issued Price”), (y) the
aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for
the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions),
and (z) the volume weighted average trading price of the Company’s Class A common stock during the 20 trading day period
starting on the trading day after the day on which it consummates its initial business combination (such price, the “Market Value”)
is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher
of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to
the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.
Note 9 — Fair Value Measurements
Fair value is defined as
the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
|
● |
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
|
● |
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
|
● |
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
The following table presents
information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2022 and December 31,
2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
| |
September 30, 2022 | | |
Quoted Prices In Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Description | |
| | |
| | |
| | |
| |
Assets: | |
| | |
| | |
| | |
| |
Mutual Funds held in trust account | |
$ | 346,698,074 | | |
$ | 346,698,074 | | |
$ | — | | |
$ | — | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Warrant liabilities | |
| 527,718 | | |
| 343,850 | | |
| — | | |
| 183,868 | |
| |
$ | 347,225,792 | | |
$ | 347,041,924 | | |
$ | — | | |
$ | 183,868 | |
| |
December 31, 2021 | | |
Quoted Prices In Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Description | |
| | |
| | |
| | |
| |
Assets: | |
| | |
| | |
| | |
| |
Mutual Funds held in trust account | |
$ | 345,018,988 | | |
$ | 345,018,988 | | |
$ | — | | |
$ | — | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Warrant liabilities | |
| 9,089,893 | | |
| 5,863,850 | | |
| — | | |
| 3,226,043 | |
| |
$ | 354,108,881 | | |
$ | 350,882,838 | | |
$ | — | | |
$ | 3,226,043 | |
At September 30, 2022 and
December 31, 2021, the Company use the quoted stock price in the active market to value the public warrants and a Monte Carlo simulation
model to value the private placement warrants with changes in fair value charged to the statements of operations. The estimated fair value
of the private placement warrant liability is determined using Level 3 inputs. Inherent in a binomial options pricing model are assumptions
related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility
of its shares of common stock based on historical volatility that matches the expected remaining life of the warrants. The risk-free interest
rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of
the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is
based on the historical rate, which the Company anticipates to remain at zero.
Transfers to/from Levels
1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and nine months ended
September 30, 2022. During the year ended December 31, 2021, there was a transfer of the public warrants from Level 3 to Level 1
due to a valuation of the public warrants using the quoted stock price in the active market.
The following table provides
quantitative information regarding assumptions used to determine Level 3 fair value measurements:
| |
At September 30,
2022 | | |
At December 31, 2021 | |
Stock price | |
$ | 9.82 | | |
$ | 9.73 | |
Strike price | |
$ | 11.50 | | |
$ | 11.50 | |
Term (in years) | |
| 5.41 | | |
| 5.91 | |
Volatility | |
| 6.9 | % | |
| 9.5 | % |
Risk-free rate | |
| 4.04 | % | |
| 1.34 | % |
Dividend yield | |
| 0 | % | |
| 0 | % |
The following table provides
a reconciliation of changes in fair value of the beginning and ending balances for our assets and liabilities classified as level 3 (private
placement warrants):
| |
Warrant | |
| |
Liability | |
Fair value at January 1, 2022 | |
$ | 3,226,043 | |
Change in fair value | |
| (1,848,252 | ) |
Fair value at March 31, 2022 | |
| 1,377,791 | |
Change in fair value | |
| (872,433 | ) |
Fair value at June 30, 2022 | |
$ | 505,358 | |
Change in fair value | |
| (321,490 | ) |
Fair value at September 30, 2022 | |
$ | 183,868 | |
| |
Warrant Liability | |
Fair value at January 1, 2021 | |
$ | - | |
Initial value at IPO date | |
| 23,290,337 | |
Change in fair value | |
| 637,123 | |
Fair value at March 31, 2021 | |
| 23,927,460 | |
Transfer of public warrants from level 3 to level 1 | |
| (15,595,052 | ) |
Change in fair value | |
| (2,692,406 | ) |
Fair Value at June 30, 2021 | |
| 5,640,002 | |
Change in fair value | |
| (1,964,432 | ) |
Fair Value at September 30, 2021 | |
$ | 3,675,570 | |
Note 10 — Subsequent Events
On November 10, 2022, the Company filed a definitive proxy statement
for the Special Meeting to, among other things, approve proposals to amend the Company’s charter and trust agreement to change the
date by which the Company would be required to consummate a business combination from March 5, 2023 to a date to be determined by the
board, in its sole discretion, no later than December 30, 2022.